The Local Lymph Node Assay (LLNA) is an internationally recognized in vivo method for evaluating the skin sensitization potential of medical devices, performed in accordance with ISO 10993-10. This technical guide explains the assay principle, sample preparation, testing procedure, Stimulation Index interpretation, and its role in global regulatory submissions such as FDA, EU MDR, and NMPA approvals.
Technical Overview
The Local Lymph Node Assay (LLNA) is a murine-based test method used to evaluate the skin sensitization (Type IV delayed-type hypersensitivity) potential of medical devices and device extracts. Within the framework of ISO 10993-1, sensitization is one of the mandatory endpoints of the biological evaluation of medical devices, and ISO 10993-10 specifies the test strategies used to assess it. The current edition, ISO 10993-10:2021, formally incorporates the LLNA, including the LLNA:BrdU-ELISA variant, as a scientifically validated alternative to traditional guinea pig methods such as the Maximization Test (GPMT) and the Buehler test.
The scientific basis of the LLNA rests on the mechanism of contact sensitization: when a sensitizing chemical penetrates the skin, it is processed by Langerhans cells and presented to T lymphocytes in the draining auricular lymph nodes, triggering allergen-specific T-cell proliferation. The assay quantifies this proliferative response rather than relying on visual scoring of erythema and edema. Following repeated topical application of the test sample to the ears of mice, the incorporation of 5-bromo-2'-deoxyuridine (BrdU) into the DNA of dividing lymphocytes is measured by ELISA, and the result is expressed as a Stimulation Index (SI). An SI value of 3.0 or greater indicates a positive sensitization response.
Compared with guinea pig protocols, the LLNA offers significant animal welfare and scientific advantages consistent with the 3Rs principles (replacement, reduction, and refinement): it uses fewer animals, avoids the pain and stress associated with induced hypersensitivity challenge, produces quantitative and dose-responsive data, and shortens the study duration from approximately 32 days to fewer than 10 days. These attributes have led to broad regulatory acceptance by authorities worldwide and alignment with the principles of OECD Test Guideline 429.
Testing Samples
Skin-Contacting Devices
Devices with prolonged or repeated skin contact carry the highest sensitization risk and are priority candidates for LLNA evaluation. Typical examples include wound dressings, transdermal patches, electrocardiogram electrodes, elastic bandages, compression garments, surgical gloves, continuous positive airway pressure masks, and prosthetic liners. Extractable chemical species such as rubber accelerators, residual monomers, plasticizers, adhesives, and colorants are common drivers of sensitization in these products.
Mucosal and Externally Communicating Devices
Devices contacting breached or compromised surfaces, or indirectly contacting blood, are also evaluated for sensitization. Examples include urinary catheters, endotracheal tubes, infusion sets, intravenous cannulae, hemodialysis tubing, and orthodontic appliances. Extracts prepared from these devices are tested to characterize the hazard of migratable substances.
Implantable Devices
Long-term implants such as orthopedic implants, dental materials, breast implants, pacemaker leads, and absorbable scaffolds require sensitization assessment as part of their biological evaluation, since leachable degradation products and residual processing chemicals can act as haptens.
Device Materials, Components, and Extracts
In addition to finished devices, the LLNA can be applied to raw materials, polymeric compounds, cure systems, coatings, inks, adhesives, and candidate formulations during design and material selection. Test articles are typically prepared as aqueous and non-aqueous extractions in accordance with ISO 10993-12, using polar media (such as 0.9% sodium chloride solution or water) and non-polar media (such as sesame seed oil) at standard ratios of surface area to extraction volume.
Testing Items
Core parameters and deliverables of a standard medical device LLNA program include the following:
- Stimulation Index (SI) determination for each test group, calculated as the ratio of BrdU incorporation in treated animals relative to the concurrent vehicle control group.
- Positive response criterion evaluation, with an SI greater than or equal to 3.0 indicating classification of the test sample as a skin sensitizer.
- Dose-response characterization across multiple concentrations or extraction conditions, with estimation of the EC3 value where applicable.
- Assay validity controls, including a positive control article such as mercaptobenzothiazole or hexyl cinnamic aldehyde, which must achieve an SI of 3.0 or higher for the assay to be considered valid.
- Clinical observations, body weight monitoring, ear thickness or ear erythema scoring, and mortality checks throughout the in-life phase.
- Polar and non-polar extract testing to cover both water-soluble and lipophilic leachables.
- Comprehensive study report suitable for inclusion in ISO 10993-1 biological evaluation files and regulatory submissions.
Testing Methods
The LLNA:BrdU-ELISA procedure specified in ISO 10993-10:2021 is the most widely adopted protocol for medical device extracts. Female mice of an appropriate strain, typically CBA/Ca, CBA/J, or BALB/c, aged approximately 8 to 12 weeks, are randomly assigned to test, vehicle control, and positive control groups. The general study flow is as follows:
- Extraction preparation: device samples are extracted in polar and non-polar vehicles under conditions defined by ISO 10993-12, commonly 37 degrees Celsius for 72 hours, with verification that the extraction does not materially alter the sample.
- Topical induction: on days 1, 2, and 3, a defined volume of test extract, typically 25 microliters per ear, is applied to the dorsal surface of both ears of each mouse.
- Rest period: on days 4 and 5, no treatment is applied, allowing the immune response to develop in the draining lymph nodes.
- BrdU administration: approximately 5 hours before lymph node harvest on day 6, animals receive an intraperitoneal or intravenous injection of BrdU, which is incorporated into newly synthesized DNA of proliferating lymphocytes.
- Lymph node processing: the auricular lymph nodes are excised and pooled per animal or per group, and single-cell suspensions are prepared.
- Quantification: BrdU incorporation is measured using a commercially available cell proliferation ELISA, and optical density values are used to compute the Stimulation Index for each treatment group.
Interpretation follows the decision criteria of ISO 10993-10: an SI of 3.0 or greater, supported by a dose-related response and a valid positive control, leads to classification of the test article as a sensitizer. Where the LLNA is technically unsuitable, for example due to test article interference with the ELISA endpoint or poor dermal penetration of highly hydrophilic extracts, the guinea pig maximization test or Buehler assay may be used instead. Increasingly, in vitro methods described in the OECD Test Guideline 442 series, including the direct peptide reactivity assay, keratinocyte-based reporter gene assays, and human cell line activation tests, are used as screening tools within integrated approaches to testing and assessment, although in vivo confirmation is still frequently requested by regulators for device registration.
All studies should be conducted in laboratories compliant with Good Laboratory Practice where required by the target jurisdiction, with institutional animal care and use committee approval and adherence to national animal welfare legislation.
Applications
LLNA sensitization data support a wide range of regulatory and product development objectives:
- Regulatory market clearance and approval, including United States FDA 510(k) and PMA submissions, European Union MDR technical documentation, China NMPA registration, Health Canada licensing, and Japanese PMDA filings, all of which reference ISO 10993-10 within the ISO 10993-1 evaluation framework.
- Biological evaluation reports and risk management files prepared in alignment with ISO 10993-1 and ISO 14971, demonstrating that sensitization risks are controlled to acceptable levels.
- Material and supplier selection during design control, allowing early screening of polymers, elastomers, adhesives, and cure systems before design freeze.
- Chemical characterization and toxicological risk assessment programs, where LLNA results complement extractables and leachables data generated under ISO 10993-17 and ISO 10993-18.
- Change control, supporting requalification when materials, manufacturing processes, sterilization methods, or packaging change.
- Root cause investigation of adverse event reports and complaint handling involving suspected allergic reactions in clinical use.
FAQ
What does a Stimulation Index of 3.0 mean? The Stimulation Index is the ratio of lymphocyte proliferation, measured as BrdU incorporation, between the treated group and the vehicle control group. An SI of 3.0 or greater, together with a valid positive control and a plausible dose-response, indicates that the test sample should be classified as a skin sensitizer under ISO 10993-10.
Why is the LLNA preferred over guinea pig tests for medical devices? The LLNA uses substantially fewer animals, avoids painful hypersensitivity challenge procedures, delivers quantitative and reproducible results, and completes in approximately one week versus several weeks for guinea pig protocols. It therefore better fulfills the 3Rs principles while providing robust scientific data.
Which extraction solvents are used? Consistent with ISO 10993-12, devices are extracted in both a polar vehicle, commonly 0.9% sodium chloride solution or water, and a non-polar vehicle, commonly sesame seed oil, to ensure that both hydrophilic and lipophilic leachable substances are evaluated.
What mouse strain is used? The standard assay uses young adult female CBA-strain mice, such as CBA/Ca or CBA/J, typically 8 to 12 weeks of age at the start of dosing, as specified in ISO 10993-10 and OECD Test Guideline 429.
Can in vitro sensitization tests replace the LLNA? In vitro methods under OECD Test Guideline 442 are valuable screening tools, but regulatory authorities generally still expect in vivo confirmation such as the LLNA for medical device registrations unless a strong scientific justification and chemical characterization data support a purely in vitro conclusion.
How long does an LLNA study take? The in-life phase lasts approximately 6 days, and with extraction, dosing, laboratory analysis, and reporting, a complete study is typically delivered within 4 to 8 weeks, significantly faster than guinea pig sensitization studies.